To date, RTS,S, a subunit vaccine based on CSP, is the only malaria vaccine candidate to show efficacy in phase III clinical trials, conferring 50% protection in preventing malaria and 45% efficacy in preventing severe disease (32). The gene discussed is DNAJC5; the disease is malaria.